Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer

The study is to investigate the efficacy and safety of apatinib for the first-fine treatment in elderly patients with locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction, unable or unwilling to chemotherapy, through progression-free survival (PFS). Apatinib will be given to patients with an efficacy assessment of stable disease (SD), partial response (PR), or complete response (CR) every 2 cycles. Patients were assigned to 500 mg/d apatinib continually until disease progression or intolerable toxicity or patients withdrawal of consent. The dose of apatinib may

Trial Details

NCT ID
NCT03219593
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Bengbu Medical University
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Apatinib mesylate tablets
Locations (sample)
  • Bengbu, Anhui, China|32.94083,117.36083

Key Eligibility Criteria

  • Patients with histologically proven primary locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;
  • Age ≥ 65 years;
  • ECOG Performance Status: 0-2;
  • No previous anti-cancer therapy for the locally advanced or metastatic disease;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →